Pages that link to "Q74563041"

The following pages link to 3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study (Q74563041):

Displaying 34 items.

• Glycosylation of glycolipids in cancer: basis for development of novel therapeutic approaches (Q21129299) (← links)
• Anti-GD2 antibody 3F8 and barley-derived (1 → 3),(1 → 4)-β-D-glucan: A Phase I study in patients with chemoresistant neuroblastoma (Q33408675) (← links)
• Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma (Q33597441) (← links)
• Pediatric Rhabdomyosarcoma (Q33842070) (← links)
• New aspects of neuroblastoma treatment: ASPHO 2011 symposium review (Q33922797) (← links)
• Anti-GD2 Strategy in the Treatment of Neuroblastoma (Q34243887) (← links)
• Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy (Q34541113) (← links)
• Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I study. (Q34877582) (← links)
• Posterior reversible encephalopathy syndrome in neuroblastoma patients receiving anti-GD2 3F8 monoclonal antibody (Q35077759) (← links)
• Comparison of pain outcomes between two anti-GD2 antibodies in patients with neuroblastoma. (Q35587509) (← links)
• Ligands Binding to Cell Surface Ganglioside GD2 Cause Src-Dependent Activation of N-Methyl-D-Aspartate Receptor Signaling and Changes in Cellular Morphology (Q35739810) (← links)
• Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-GD2 immunotherapy and isotretinoin: a prospective Phase II study (Q35798960) (← links)
• Surface antigen expression and complement susceptibility of differentiated neuroblastoma clones (Q35809851) (← links)
• Anti-proliferative and pro-apoptotic activity of GD2 ganglioside-specific monoclonal antibody 3F8 in human melanoma cells (Q36060249) (← links)
• PPARgamma in Neuroblastoma (Q36678476) (← links)
• Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin (Q36782374) (← links)
• Perspectives on Anti-Glycan Antibodies Gleaned from Development of a Community Resource Database (Q37105366) (← links)
• Anti-CD3 × anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets (Q37220750) (← links)
• Immune therapies for neuroblastoma (Q37431356) (← links)
• Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma. (Q37624276) (← links)
• Anti-GD2 antibody therapy for GD2-expressing tumors (Q37702283) (← links)
• Radioimmunotherapy of Solid Tumors: Searching for the Right Target (Q37804904) (← links)
• Treatment of high-risk neuroblastoma with anti-GD2 antibodies (Q37820755) (← links)
• Development of treatment strategies for advanced neuroblastoma (Q38010377) (← links)
• Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy (Q38916529) (← links)
• New strategies in refractory and recurrent neuroblastoma: translational opportunities to impact patient outcome (Q39639490) (← links)
• Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen (Q41901715) (← links)
• An anti-GD2 monoclonal antibody enhances apoptotic effects of anti-cancer drugs against small cell lung cancer cells via JNK (c-Jun terminal kinase) activation (Q44083589) (← links)
• Biological therapy for pediatric malignancy: current perspectives (Q46390752) (← links)
• Therapeutic Antibodies to Ganglioside GD2 Evolved from Highly Selective Germline Antibodies. (Q47945436) (← links)
• A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931. (Q55501991) (← links)
• Recent advances in neuroblastoma (Q56637924) (← links)
• Monitoring Immune Responses in Neuroblastoma Patients during Therapy (Q89896175) (← links)
• Advances in Anti-GD2 Immunotherapy for Treatment of High-risk Neuroblastoma (Q92529625) (← links)